Yes, when the biggest risk is lateral movement through flat or converged networks. Microsegmentation gives the clearest early containment benefit because it reduces the blast radius first, then creates a stronger foundation for identity, device, and data controls that follow.
Why microsegmentation should come first when lateral movement is the main concern
For pharmaceutical environments, the sequencing question is less about ideology and more about where the first meaningful containment boundary sits. If flat corporate, lab, manufacturing, or OT-adjacent networks still allow broad east-west reach, microsegmentation usually delivers the fastest reduction in blast radius. That makes it a practical early control when broader zero trust programs are still being planned.
Microsegmentation is most valuable where shared networks, legacy systems, and mixed-trust zones create a wide lateral path. In pharma, that often means separating research systems from enterprise services, production from development, and third-party access from internal administration. The control does not replace zero trust, but it gives the later program something enforceable to build on. NIST’s zero trust model explicitly includes micro-segmentation as part of the architecture, which is why it works well as an early containment layer rather than a side project.
That sequencing matters because broad zero trust rollouts often start with identity policy, device posture, and access decisions, while microsegmentation immediately narrows the paths an attacker can use after an initial foothold. A Zero Trust Identity Guide is useful here because it shows how segmentation, identity-centric policy, and phased rollout fit together instead of competing for priority.
What microsegmentation changes before full zero trust is in place
Microsegmentation changes the environment from one where compromise in a single subnet can become a broader incident to one where each workload, zone, or application tier has a smaller trust envelope. That is especially relevant in pharmaceutical settings where sensitive data, regulated workloads, and vendor-managed systems often coexist. If one part of the environment is weaker, segmentation prevents that weakness from becoming a universal access path.
The main practical gain is containment, not perfection. Even when authentication, device checks, and privileged access controls are still maturing, a segmented network can stop simple east-west probing, limit ransomware spread, and reduce the number of systems that need emergency response. The architecture is strongest when paired with workload identity and service-to-service trust rules, because those controls make the segmentation policy more precise than IP ranges alone. The Guide to SPIFFE and SPIRE is a strong companion reference for teams that want to connect segmentation to workload identity rather than static network boundaries.
Microsegmentation also creates clearer migration paths. Once teams can prove that a lab instrument network, a manufacturing cell, or a vendor jump path is isolated, they can extend zero trust controls more confidently to identity, device, and data layers. For that reason, microsegmentation is often the control that turns zero trust from a strategic slogan into an enforceable network design.
When to delay, sequence, or combine it with other controls
Microsegmentation should move first when the dominant concern is blast radius, but it should not be treated as a universal substitute for identity-led controls. If the biggest exposure is weak authentication, excessive privilege, or unmanaged machine credentials, the program still needs access governance and workload identity in parallel. The best sequencing is to use segmentation to reduce immediate exposure while the broader zero trust stack catches up.
Pharmaceutical teams should also avoid designing segmentation so tightly around current topology that every future change becomes an exception. That creates brittle policies, slow deployments, and pressure to reopen segments. A better pattern is to segment around business functions, trust levels, and critical data flows, then map identities and services into those zones. NHIMG’s IAM and IGA Basics helps connect that network design to the identity and entitlement controls that usually follow.
A related consideration is whether the environment already has strong east-west visibility. If traffic telemetry is poor, segmentation policy may be hard to validate, and false confidence becomes a risk. In that case, the first rollout should include monitoring of blocked flows, allowed exceptions, and unexpected cross-zone communication so the program can prove containment rather than assume it.
Risk and Threat Considerations
Flat or lightly controlled networks make pharmaceutical organisations easier to traverse once an attacker gets one foothold. That raises the value of microsegmentation because the main threat is not always initial compromise, it is what happens after compromise, when malware, insiders, or stolen credentials are used to move laterally toward sensitive research, manufacturing, or regulated systems.
Failure mechanism: A compromise in one endpoint, server, or vendor entry point can be used to scan, authenticate, or pivot across shared network space when east-west traffic is not constrained.
Impact: The likely result is broader blast radius, slower containment, and a higher chance that production, research, or sensitive data environments are affected in the same incident.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5, NIST Zero Trust (SP 800-207), CIS Controls v8 and NIST CSF 2.0 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | SC-7 — Boundary Protection | Microsegmentation is a boundary-control problem in flat networks. |
| AC-4 — Information Flow Enforcement | Segmentation enforces which workloads and zones may communicate. | |
| Recommendation — Define segmented trust boundaries and restrict east-west traffic to approved flows. Enforce information-flow rules between production, lab, and vendor zones. | ||
| NIST Zero Trust (SP 800-207) | N/A — Microsegmentation | Zero trust architecture explicitly uses microsegmentation to limit lateral movement. |
| Recommendation — Implement microsegmentation early to reduce blast radius before broader policy rollout. | ||
| CIS Controls v8 | CIS-12 — Network Infrastructure Management | Network segmentation and controlled paths are core hardening measures. |
| Recommendation — Segment networks and validate that only required flows remain open. | ||
| NIST CSF 2.0 | PR.AA-05 — Identity Management, Authentication, and Access Enforcement | Zero trust rollout depends on identity-based access enforcement after containment. |
| Recommendation — Tie segmented access to strong identity enforcement and least privilege. | ||
Practitioner Guidance
What to prioritise: Start with the zones that matter most to containment, usually production, regulated data stores, lab systems, and remote access paths into those environments. Prioritise the paths an attacker would use after initial access, not the easiest segments to draw on a network diagram.
What to verify: Confirm that every allow rule has an owner, a business justification, and a measurable dependency. If you cannot explain why a flow must remain open, it is probably carrying historical access rather than operational need.
Decision rule: If the environment still has large shared trust zones, microsegmentation should come before a full zero trust rollout; if identity hygiene and privilege sprawl are the larger weakness, treat segmentation as the containment layer while those controls are remediated in parallel.
Practitioner takeaway: For pharma, the right sequence is usually containment first, then policy refinement, because reducing blast radius creates breathing room for the slower work of identity, device, and data enforcement.
Related resources from NHI Mgmt Group
- Should healthcare teams prioritise multi-factor authentication before broader Zero Trust projects, or should both move together?
- Should organisations prioritise Zero Trust for machine identities before broader IAM changes?
- What controls should teams prioritise first in a Zero Trust rollout?
- What should IAM teams prioritise when Zero Trust rollout stalls?